HORIEN Biotech Breaks Ground in Thailand and Wins U.S. Patent for Biodegradable Ureteral Stent

TAICHUNG, Taiwan – On September 8, 2026, HORIEN Biochemical Technology Co., Ltd. (TPEx: 7814) announced a double‑win that could reshape its footprint across Asia and the United States.

First, the company received Class 4 clearance from the Thai Food and Drug Administration for three new regenerative‑medicine devices. Second, a U.S. patent was granted for its pioneering biodegradable ureteral stent – a single‑use solution that disappears once a patient heals, sparing them a second, uncomfortable procedure.

“Thailand is a pivotal cornerstone in our Southeast Asian expansion,” says Hsin‑Yu Ho, General Manager of HORIEN. “These approvals validate the safety and efficacy of our collagen platform, and the U.S. patent showcases the breadth of our R&D, from oral care to urology.”

The Thai‑approved lineup all stems from HORIEN’s porcine‑derived collagen technology, processed through dehydrothermal treatment and meticulous decellularisation. The three products are:

• Horien Collagen Bone Graft Matrix – a porous scaffold designed for guided bone regeneration, encouraging natural bone growth while providing structural support.
• Horien Collagen Matrix – a biocompatible plug and sheet that quickly absorbs fluids, stabilises clots, and protects surgical or dental wounds.
• Horien Extracellular Membrane – a resorbable extracellular matrix harvested from porcine small‑intestinal submucosa, ideal for guided tissue regeneration and alveolar ridge preservation.

Beyond the product suite, the newly granted U.S. invention patent covers a biodegradable ureteral stent that safely degrades after the urinary tract heals. By eliminating the need for a second endoscopic removal, the device cuts infection risk and improves patient comfort—a clear win for both clinicians and patients.

HORIEN isn’t just celebrating papers; it’s actively seeking exclusive, strategic distribution partners in Thailand. Ideal partners will have strong footholds in dental, surgical, or regenerative‑medicine channels, robust regulatory know‑how, and a commitment to clinician education.

Partners can look forward to:

• Immediate market entry with a Thai FDA‑approved Class 4 portfolio.
• Access to ISO‑ and GMP‑certified manufacturing facilities that meet global quality standards.
• Comprehensive training, scientific support, and co‑marketing resources.

Why Thailand now? The country's healthcare market is on a growth trajectory. According to Grand View Research, the dental equipment and consumables sector was worth US$383 million in 2024 and is projected to reach US$570 million by 2030 (CAGR ≈ 6.9%). General surgery devices are expected to climb from US$164 million to US$258 million (CAGR ≈ 7.9%), while regenerative‑medicine solutions could more than double to US$114 million (CAGR ≈ 10.1%). These numbers point to a rising demand for premium, regenerative technologies—exactly where HORIEN’s collagen platform sits.

Back in Taiwan, the “Horien” Collagen Matrix alone generates over US$1.2 million in annual revenue, proving both clinical acceptance and commercial viability. HORIEN hopes to replicate that success across Thailand’s bustling clinics and hospitals, while the U.S. patent opens doors to high‑value urological markets worldwide.

In short, HORIEN is moving from a strong regional player to a truly global contender, leveraging regulatory wins, intellectual‑property strength, and carefully chosen partnerships to drive the next wave of regenerative‑medicine adoption.